A large, multi-institutional analysis using the International Association for the Study of Lung Cancer (IASLC) staging database shows that molecular alterations in mesothelioma cells significantly influence survival. Tracking these changes may also improve the ability to predict survival beyond what is currently being used for these assessments.
Mesothelioma Analysis Identifies Key Tumor Suppressor Gene Alterations
The multi-institutional study, a collaboration of scientists from Memorial Sloan Kettering Cancer Center, University of Chicago Medicine, and other major institutions, analyzed 556 mesothelioma patients diagnosed between 2013 and 2022, and performed next-generation sequencing on 260 tumors to characterize their genetic alterations. The cohort’s makeup included 77.7% patients over the age of 65, 72.7% male, with 77.5% having epithelioid tumors—the most common mesothelioma subtype and the one with a relatively better prognosis than biphasic (13.1% of the study group) or sarcomatoid (9.4% of the study group) types.
The most common molecular alterations identified within the mesothelioma cells were BAP1 mutations (seen in 55.0% of tumors), CDKN2A alterations (seen in 36.2% of tumors), NF2 alterations (seen in 23.8% of tumors), TP53 alterations (seen in 18.1% of tumors), and SETD2 alterations (seen in 8.8% of tumors). These findings confirm that tumor suppressor gene disruption is a dominant feature of the rare cancer’s biology, and that, unlike many cancers driven by activating mutations, mesothelioma’s growth is, in part, a loss of protective cellular pathways that would normally prevent uncontrolled growth.
Mesothelioma Study Shows Prognostic Impact of Specific Mutations
The most scientifically important findings from the mesothelioma study came from the survival analyses, which showed that certain molecular alterations are strongly associated with outcomes. The genomic alterations linked to worse survival included CDKN2A mutations, NF2 mutations, and TP53 mutations. While BAP1 alterations were associated with better mesothelioma survival, the results suggest that CDKN2A loss may be one of the strongest molecular predictors of poor survival. PD-L1 immune biomarker expression did not demonstrate a statistically significant association with overall survival, suggesting a limited prognostic value.
The best mesothelioma predictive model combined both clinical and molecular features, integrating BAP1 alterations and mutations in CDKN2A, NF2, or TP53 with clinical variables. These findings show that molecular testing will be important for future classification systems, suggesting that genomic biomarkers may help with prognosis, guide treatment selection, and inform future staging revisions.
If you or someone you love has been diagnosed with mesothelioma, the Patient Advocates at Mesothelioma.net are here to help. Contact us today at 1-800-692-8608 to learn more.
